Knee Implants Market: Global Industry Analysis and Market Forecast 2016 2021

Knee Implants

Summary:

The global market overview for knee implants looks promising considering advances in computer–assisted total knee implants as well as other technological platforms. The knee implants market will continue to grow due to an aging population in much of the world. Increasing life spans and lifestyles impact the number of individuals with knee subject to failure, thereby increasing demand for knee replacement procedures. Additionally, the growing health awareness among masses, along with increase in the spending capacity of the population are propelling the market growth.

Long–term Outlook: Global knee implants market is projected to reach more than US$ 7 Billion by 2021.

Knee Implants Market: Country–wise Outlook

United States hold the highest share with more than 60% in 2015, and is expected that United States will maintain its position in the forecasting period. International markets such as India, China and Japan will show positive growth in the future and market share will increase to XX% by the year 2021. The opportunity is immense in the emerging markets, as there is a large untapped population with the surgical need of knee implants.

Browse full report @ http://www.aarkstore.com/healthcare/221642/knee-implants-market-global-industry-analysis-and-market-forecast-2016-2021

 

Knee Implants Market: Key Players Outlook
 

The global knee implants market is dominated by Zimmer Biomet, Stryker, DePuy Synthes and Smith & Nephew. The three large players in the knee implants market are Zimmer Biomet, DePuy Synthes and Stryker combined, they comprise almost more than 80% of the market. Other nominal yet important players of this market include Smith & Nephew, Exactech, DJO Global and many more. It is expected that Zimmer Biomet will emerge as a leading company in the knee implants market in the forecasting period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, type of product and deal landscapes. The report concludes with the profiles of major players in the global knee implants market such as Zimmer Biomet, Stryker, Smith & Nephew, Exactech, DePuy Synthes(JnJ). The major market players are evaluated on various parameters such as company overview, product portfolio, and revenue of knee implants from 2008 to 2021.

The report covers in–depth analysis on:

• Market Segments
• Market Dynamics
• Historical Actual Market Size, 2008 – 2015
• Market Size & Forecast 2016 to 2021
• Competition & Companies Involved
• Deals Landscapes
• Market Growth Drivers and Challenges

Global – Knee Implants Market: Key Company Analysis

• Zimmer Biomet
• Stryker
• DePuy Synthes (Johnson & Johnson)
• Smith & Nephew
• Exactech
• Other Companies

Best Selling Reports :

Global Industry Heat Exchangers Market Research Report 2021

Global Knee High Socks Sales Market Report 2021

 

 

 

ASIA-PACIFIC UNIFIED COMMUNICATION-AS-A-SERVICE MARKET FORECAST TO 2020

Unified Communication

The Asia-Pacific unified communication-as-a-service market is estimated to grow at a CAGR of 12.5% during the forecast period of 2015-2020. The market has been broadly classified by vertical, component, organization size, and geography. Among verticals, the BFSI segment is estimated to account for the largest share of the Asia-Pacific unified communication-as-a-service in 2016. However, the healthcare vertical is expected to grow at the highest CAGR of 13.6% during the forecast period.

Increase in the integration of multiple communication tools and low deployment & service cost, along with preference of pay-per-use model, are the factors driving the growth of the Asia-Pacific unified communication-as-a-service market. Moreover, to ensure data security, use of UCaaS platform is more prevalent as enterprises are able to use different architectures to communicate. It empowers each channel to encrypt the information that is being transferred across the networks. As a result, the information cannot be decrypted by malicious attackers.

In 2016, China is estimated to lead Asia-Pacific unified communication-as-a-service market with a market share of 20.4%. It is expected to grow at a CAGR of 13.4% during the forecast period 2016 to 2021. China has been leading the Asia-Pacific unified communication-as-a-service market because of the high popularity of the pay-per-use based pricing model in this country. It facilitates the best-in-class approach for each communication application and a single platform for most communication processes. In Australia, the UCaaS market is anticipated to grow at a significant pace during the forecast period owing to the high level of penetration of UCaaS in SMBs and increasing demand for BYOD and enterprise mobility.

Mitel Networks Corporation (U.S.), Avaya (U.S.), Cisco (U.S.), Microsoft (U.S.), and Vodafone Group Plc (U.K.) are the key players operating in the Asia-Pacific unified communication-as-a-service market.

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis—industry analysis (industry trends and PEST analysis), market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging- and high-growth segments of the Asia-Pacific unified communication-as-a-service market, high-growth countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help them in garnering a greater market share. Firms purchasing the report could use any one or combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market share.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on UCaaS solutions and services offered by the top 10 players in the Asia-Pacific UCaaS market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the market.
  • Market Development: Comprehensive information about lucrative emerging markets.
  • Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the market.
  • Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading market players.

Best Selling Reports:

Asia-Pacifics ICT Spends in Pharmaceuticals Sector – Future Perspective to 2019

Global Unified Communication as a Service Industry 2016 Market Research Report

Repsol S.A. (REP) – Financial and Strategic SWOT Analysis Review

Repsol

Summary

Repsol S.A. (REP) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the companys key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

Highlights

Repsol S.A. (Repsol) is an integrated oil and gas company. It explores for, develops and produces crude oil and natural gas; transports oil products, liquefied petroleum gas (LPG) and natural gas; refines and produces petroleum products; and retails oil products, oil derivatives, petrochemicals, LPG and natural gas. It also carries out the generation, transportation, distribution and supply of electricity. The company operates six refineries in Spain and Peru. Its outlets are in Spain, Portugal, Peru, and Italy. Repsol carries out utility business through its interest in Gas Natural Fenosa. It has presence in Europe, Latin America, North America, Africa, Asia and Oceania. Repsol is headquartered in Madrid, Spain.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the companys business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The companys core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Best Selling Reports :

Repsol S.A. (REP) – Oil & Gas – Deals and Alliances Profile

FirstGroup plc (FGP) – Financial and Strategic SWOT Analysis Review

Landstar System, Inc. (LSTR) – Financial and Strategic SWOT Analysis Review

U.S. Radiation Dose Management Market Forecast till 2020

The purpose of this report is to cover the definition, description, and forecast of the U.S. radiation dose management market. It involves deep dive analysis of market segmentation, which comprises of product type, application, and end user. The report also gives the deep insight on, and strategic analysis of, the key players of this market.

The U.S. radiation dose management market is expected to grow at a CAGR of 49.7% from 2015 to 2020.

In this report, the U.S. radiation dose management market has been classified on the basis of product type, application, and end user. Based on product type, the market has been segmented into services and software. Based on application, the market has been segmented into computed tomography, fluoroscopy, radiography & mammography, and nuclear medicine. Based on end user, the market has been segmented into hospitals, diagnostic centers, and research institutes & academic medical centers.

Software is the fastest-growing segment of the market, and is expected to grow at the highest CAGR of 50.3% from 2015 to 2020. Factors such as growing awareness among stakeholders, various industry initiatives taken for radiation dose management through various scientific and media reports, campaigns and safety programs, along with various government initiatives have led to the increased awareness among patients. The growing concern for the risk of over-exposure to radiations is another factor expected to drive the growth of the U.S. radiation dose management market.

The major companies operational in this market include Bayer AG (Germany), GE Healthcare (U.K.), PACSHealth, LLC (U.S.), and Sectra AB (Sweden). Other players includes QAELUM NV (Belgium), Philips Healthcare (Netherlands), FUJIFILM Holdings Corporation (Japan), Novarad Corporation (U.S.) Siemens Healthcare (Germany), Agfa HealthCare (Belgium), Toshiba Medical Systems Corporation (Japan), Bracco Imaging S.p.A (Italy), and McKesson Corporation (U.S.). These companies have adopted various strategies, such as mergers & acquisitions and partnerships, among others, to achieve growth in the U.S. radiation dose management market.

Request for an in-depth table of contents for this report 

Reasons to Buy the Report:

From an insight perspective, this research report has focused on various levels of analysis—industry analysis (industry trends, and PEST analysis), market share analysis of top players, supply chain analysis, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging- and high-growth in the country and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to analyze the market, which in turn will help the firms in achieving a greater market share. Firms purchasing the report could use any one or combination of the below mentioned strategies for strengthening their market share.

 

  • Market Penetration: Comprehensive information on top players in the S. radiation dose management market

 

  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the S. radiation dose management market

 

  • S. radiation dose management market Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the U.S. radiation dose management market

 

 Best Selling Reports :

U.S. Army Institute of Surgical Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Global Radiation Dose Management Industry 2015 Market Research Report

 

 

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 – Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

Breast CancerSummary

Breast cancer, a malignant neoplasm, is the second-most common cancer and the most common cancer in women worldwide, accounting for 16% of all female cancers, making the disease exceedingly prevalent. In the past, breast cancer occurred less in women in Asia than women in Western countries. However, recent studies show that breast cancer is being diagnosed more frequently in women living in Asia, especially among younger women.

There have been wide-reaching changes in the breast cancer market over the past four decades, particularly in relation to the usage of targeted therapies, which has increased significantly. The marketed products landscape comprises a wide range of treatment options, including hormonal therapies, chemotherapies, combination therapies and targeted therapies. The market is set to be driven by a number of new approvals for drugs and an increased uptake of premium targeted therapies. Nevertheless, significant unmet need remains for products that can improve overall survival rate, time to disease progression, and overall response.

Scope

The current breast cancer market contains novel products, including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent.
– What are the competitive advantages of the existing novel drugs?
– Are these targeted therapies used to the same magnitude in all the countries assessed?
– What are the factors contributing to the uptake of these drugs in each country?
With over 700 active pipeline molecules, most of the investigational drug candidates are being evaluated for the first-line or second-line treatment of advanced-stage breast cancer, featuring new combination therapies, targeted therapies, and promising immunotherapies, as well as chemotherapy drug candidates.
– Which classes of novel drugs are most prominent within the pipeline?
– Is there strong potential for the pipeline to address unmet needs within the breast cancer market?
– Which Asia-Pacific countries should expect a late launch and a lower uptake of the late-stage pipeline drugs?
Analysis of clinical trials since 2006 identified that the failure rates of breast cancer molecules were highest in Phase II (41%), with the overall attrition rate for breast cancer in development being 61%.
– How do failure rates vary by product stage of development, molecule type, and mechanism of action?
– How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2014-2021 period, the value of the Asia-Pacific markets for breast cancer therapeutics is expected to increase at a compound annual growth rate of 8.5%, from $1.9 billion to over $3.4 billion.
– Which markets make the most significant contribution to the current market size?
– What are the epidemiology trends in these markets?
– Will new market entrants lead to substantial changes in annual therapy costs?
– How will different treatment usage patterns impact growth in the Asia-Pacific markets?
– What are the various trends observed in the market over the forecast period in each of the countries?
Rising breast cancer prevalence and increasing use of premium targeted therapies along with new product approvals will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.
– Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers would influence the market over the forecast period.
– What are the barriers that limit the uptake of premium-priced therapeutics in the accessed countries?
– Which factors are most likely to drive the market in these countries?

Request for an in-depth table of contents for this report 

 Reasons to buy

This report will enable you to –
– Understand the clinical context of breast cancer by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options
– Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need
– Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty
– Consider market opportunities and potential risks by examining trends in breast cancer clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action
– Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in breast cancer by examining clinical trial data and multi-scenario product forecast projections
– Compare treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain and Japan
– Discover trends in licensing and co-development deals concerning breast cancer products and identify the major strategic consolidations that have shaped the commercial landscape

Best Selling Reports :

United States Breast Imaging Technologies Sales Market Report 2021

Global Cancer Therapeutics and Biotherapeutics Sales Market Report 2021

Transition Therapeutics Inc. (TTH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

 

 

Mayo Clinic – Strategic SWOT Analysis Review

Mayo Clinic

SUMMARY

Mayo Clinic – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

– Business description A detailed description of the companys operations and business divisions.
– Corporate strategy GlobalDatas summarization of the companys business strategy.
– SWOT analysis A detailed analysis of the companys strengths, weakness, opportunities and threats.
– Company history Progression of key events associated with the company.
– Major products and services A list of major products, services and brands of the company.
– Key competitors A list of key competitors to the company.
– Key employees A list of the key executives of the company.
– Executive biographies A brief summary of the executives employment history.
– Key operational heads A list of personnel heading key departments/functions.
– Important locations and subsidiaries A list of key locations and subsidiaries of the company, including contact details.
– Key manufacturing facilities A list of key manufacturing facilities of the company.

Browse full report @ http://www.aarkstore.com/pharmaceuticals-healthcare/176704/mayo-clinic-strategic-swot-analysis-review

Highlights

Mayo Clinic (Mayo) formerly known as Mayo Clinic Jacksonville is a not-for-profit healthcare organization. The organization provides comprehensive medical facilities and programs related to healthcare education, and research and patient care services. It provides treatments for diseases such as cancer, bipolar disorder, brachial plexus injury, tumors, burning mouth syndrome, eating disorders, epilepsy, infectious diseases, lung diseases, melanoma, Alzheimers and Parkinsons disease, temporomandibular joint (TMJ) disorders, womens health, Wilsons disease and Wolff-Parkinson-White (WPW) syndrome, among others. Mayo operates through its various medical departments that include aerospace medicine, allergy, breast cancer, emergency medicine, medical genetics, pathology, radiology, oncology, neurology, nephrology, ophthalmology and others. Mayo Clinic is headquartered in Jacksonville, Florida, the US.

Reasons to Buy

– Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
– Identify potential customers and suppliers with this reports analysis of the companys business structure, operations, major products and services and business strategy.
– Understand and respond to your competitors business structure and strategies with GlobalDatas detailed SWOT analysis. In this, the companys core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
– Examine potential investment and acquisition targets with this reports detailed insight into the companys strategic, business and operational performance.

Best Selling Reports :

Mayo Clinic US – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Singapore Telecommunications Limited (Z74) – Financial and Strategic SWOT Analysis Review

Mind C.T.I. Ltd. (MNDO) – Financial and Strategic SWOT Analysis Review

 

Coronary Artery Disease -Pipeline Insights- 2016

Coronary Artery Disease

SUMMARY

Coronary Artery Disease (CAD)-Pipeline Insights, 2016, report provides in depth insights on the pipeline drugs and their development activities around the Coronary Artery Disease (CAD). The DelveInsights Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsights Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Coronary Artery Disease (CAD). DelveInsights Report also assesses the Coronary Artery Disease (CAD) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope

The report provides competitivepipeline landscape of Coronary Artery Disease (CAD)
The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
Coverage of the Coronary Artery Disease (CAD) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) and also provide company profiling
The report also gives the information of dormant and discontinued pipeline projects
Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Browse full report @ http://www.aarkstore.com/pharmaceuticals-healthcare/178947/coronary-artery-disease-cad-pipeline-insights-2016

Reasons to buy

Complete Pipeline intelligence and complete understanding over therapeutics development for Coronary Artery Disease (CAD)
Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) pipeline depth and focus of Indication therapeutics
Developing strategic initiatives to support your drug development activities.
Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Gaining a Full Picture of the Competitive Landscape for Evidencebased Decisions

Best Selling Reports :

Global Coronary Stent Devices Industry 2016 Market Research Report

PharmaPoint: Peripheral Artery Disease – Global Drug Forecast and Market Analysis to 2024

Follow

Get every new post delivered to your Inbox.

Join 214 other followers

%d bloggers like this: